Megaphone icon ETF Database is now VettaFi. Read More >
ETFdb Logo
ETFdb Logo
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • Entrepreneur ETF
    • Equity ETF
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Multi-Factor
    • Nasdaq Investment Intelligence
    • Portfolio Strategies
    • Retirement Income
    • Smart Beta
    • Thematic Investing
    • Volatility Resource
  • Database
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
    • ETFs Future-Forward 2021: An iShares Investing Symposium
    • Three Themes for 2021: An iShares & MSCI Investing Symposium
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Disruptive Technology Channel
  2. Gilded Age of Genomics Just Getting Underway
Disruptive Technology Channel
Share

Gilded Age of Genomics Just Getting Underway

Tom LydonSep 27, 2021
2021-09-27

Genomics is one of the cornerstones of disruptive growth in the healthcare sector. Relevant to investors is that genomics is still in its nascent stages, indicating that there’s a potentially lengthy runway ahead for impressive long-term gains.

One of the prime avenues for tapping that potential is the ARK Genomic Revolution Multi-Sector Fund (ARKG ). The $9.74 billion ARKG is actively managed — a favorable attribute in an arena where nimbleness and the ability to look out to the future are often rewarded.

On that note, ARKG, arguably more so than rival ETFs in this category, features strong exposure to exciting concepts, including CRISPR and precision oncology — the latter of which is just getting started and hard to come by in competing ETFs.

“We have also seen some exciting developments this year involving the use of Crispr technology in gene editing, and we will see more,” said Liisa Bayko in a Barron’s healthcare roundtable. “We are awaiting data from Editas Medicine [EDIT]  on a potential one-time therapy to restore vision in patients with a genetic disease that causes blindness. We have seen proof of concept from Intellia Therapeutics [NTLA; in late June, the company and its partner, Regeneron Pharmaceuticals (REGN), proved the efficacy of gene editing in humans, with a treatment targeting a rare eye disease].”

Bayko is a managing director and research analyst at Evercore ISI covering small- and mid-cap biotechnology companies. Regeneron and Intellia are top 10 holdings in ARKG, combining for about 6.5% of the ARK ETF’s roster. Editas Medicine commands a 1% weight in the fund.

Adding to the allure of ARKG is the fact that several of its member firms are working on drugs or treatments for which there is obvious demand (such nonalcoholic fatty liver disease (NASH)) and no adequate treatments currently on the market, and some of these companies are doing so in remarkably cost-effective fashion.

“There are two types of companies working in this area. Some are developing tools, and others are using the tools to develop drugs,” adds Bayko. “The drug developers end up being more valuable. They are uncovering new targets for treatment, and rapidly enhancing lead molecules [chemical compounds with likely therapeutic use]  in just a couple of years, with an investment of $10 million or so, versus a lot more money and time in the past.”

Another important element of the genomics thesis is its intersection with other innovative technologies, such as artificial intelligence (AI). That relationship is evident in ARKG.

“Clinically, using artificial intelligence to enable efficiencies will be critical. We have seen some innovation around the use of AI to identify the best patient populations on which to test particular drugs. Whether the drugs are more effective remains to be seen,” according to Bayko.

For more news, information, and strategy, visit the Disruptive Technology Channel.

Loading Articles...
Help & Info
  • Contact Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

Equity ETF Channel

Retirement Portfolio Redux: Is the 60%-40% Portfolio Dead?

Debbie CarlsonOct 22, 2020
2020-10-22

With the 10-year U.S. Treasury yield hovering below 1% and Federal Reserve Chairman Jerome Powell...

Equity ETF Channel

Portfolio Diversification Isn't Dead, It Was Just Sleeping

Debbie CarlsonOct 15, 2020
2020-10-15

Investors could be forgiven to think there was no reason to invest outside of the U.S. for the...

}
X